CytomX Therapeutics
CTMX
97 hedge funds and large institutions have $441M invested in CytomX Therapeutics in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 15 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 16
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
29% more capital invested
Capital invested by funds: $343M → $441M (+$98M)
8% more funds holding
Funds holding: 90 → 97 (+7)
5.6% more ownership
Funds ownership: 60.15% → 65.75% (+5.6%)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.15M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.36M |
| 3 |
BlackRock
New York
|
+$3.86M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.5M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$4.93M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.5M |
| 3 |
VMI
VHCP Management II
New York
|
-$4.48M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.33M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.03M |
CTMX Hedge Fund Activity: Q3 2017 in Review
97 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2017, worth a combined $441M — up 29% from $343M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CTMX positions and 15 closed out — a net gain of 8 holders — while 38 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.15M. The largest seller was Redmile Group, cutting an estimated $4.93M.
- 97 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2017, up from 90 in Q2 2017.
- Funds reported $441M of CytomX Therapeutics stock for Q3 2017, up 29% quarter-over-quarter.
- 23 funds opened new CytomX Therapeutics positions in Q3 2017 and 15 closed out, a net change of +8 holders.
- The largest CytomX Therapeutics buyer in Q3 2017 was Millennium Management, an estimated $8.15M added.
- The largest CytomX Therapeutics seller in Q3 2017 was Redmile Group, an estimated $4.93M sold.
Based on aggregated 13F filings for Q3 2017.